Latest Lupus Nephritis News
Over a 5-year period, the drug was well tolerated and associated with significant declines in urinary protein-creatinine ratio and mean prednisolone dose.
Death from lupus ranked 10th in women 15 to 24 years, 14th in those aged 25 to 34 and 35 to 44 years.
In a phase 2b trial, around half of patients taking the novel calcineurin inhibitor at a dose of 23.7 mg twice daily achieved complete remission at 48 weeks.
End-stage renal disease is 5-fold more likely to develop in patients with 3 or more infection-related hospitalizations versus none.
The primary outcome was reduction in proteinuria, as measured by protein-to-creatinine (P:C) ratio in a 12-hour urine collection, at 24 weeks compared with baseline.
Chemokines, cytokines, and markers of cellular damage had the most predictive power.
The development of this scale, once further validated, will give clinicians the ability to verify lupus nephritis activity without the need for an invasive kidney biopsy.
Among the findings, researchers found no association between mixed or pure histopathologic features of LN at presentation and rates of complete or partial remission.
Researchers find an increased risk of death among patients.
Athcar gel may be a treatment option for patients with treatment-resistant nephrotic syndrome.
Antimalarial protects against metabolic syndrome, countering steroid effects.
No change in interferon signature in vitamin D-deficient patients, those with vitamin D repletion.
Increased risk of systemic lupus erythematosus, lupus nephritis with copy number loss, not gain.
Urinary red blood cells undermine a composite prediction of renal outcome.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)